{"entity":{"type":"insider","cik":"0001507174","url":"/insider/0001507174","json_url":"/insider/0001507174.json","name":"LaBarre Michael J.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":70,"n_filings":37,"first":"2020-05-21","last":"2025-02-27","span_basis":"filed_date"},"name_variants":[{"name":"LaBarre Michael J.","source":"filing","n_filings":37,"first_seen":"2020-05-21","last_seen":"2025-02-27"}],"transactions":[{"id":4706984,"accession":"0001415889-25-005899","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001415889-25-005899","line_url":"/filing/0001415889-25-005899","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1697.0,"shares_display":"1,697","price_per_share":58.2807566293459,"price_display":"58.28","price_state":"stated","total_value":98902.444,"total_display":"98,902.44","total_whole":"98,902","shares_owned_after":173856.0,"shares_owned_after_display":"173,856","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-27","filed_date":"2025-02-27","scope":"insider","n_lines":2},{"id":4706971,"accession":"0001415889-25-005899","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-25-005899","line_url":"/filing/0001415889-25-005899","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":58.12442,"price_display":"58.12","price_state":"stated","total_value":581244.2,"total_display":"581,244.20","total_whole":"581,244","shares_owned_after":176053.0,"shares_owned_after_display":"176,053","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-26","filed_date":"2025-02-27","scope":"insider","n_lines":2},{"id":4706950,"accession":"0001415889-25-005899","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-25-005899","line_url":"/filing/0001415889-25-005899","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":58.05341,"price_display":"58.05","price_state":"stated","total_value":580534.1,"total_display":"580,534.10","total_whole":"580,534","shares_owned_after":186153.0,"shares_owned_after_display":"186,153","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-02-25","filed_date":"2025-02-27","scope":"insider","n_lines":2},{"id":2864094,"accession":"0001415889-24-025233","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001415889-24-025233","line_url":"/filing/0001415889-24-025233#line-6","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":53.259,"price_display":"53.26","price_state":"stated","total_value":532590.0,"total_display":"532,590.00","total_whole":"532,590","shares_owned_after":173756.0,"shares_owned_after_display":"173,756","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-16","filed_date":"2024-10-16","scope":"insider"},{"id":2864085,"accession":"0001415889-24-025233","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-24-025233","line_url":"/filing/0001415889-24-025233","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":53.7468654,"price_display":"53.75","price_state":"stated","total_value":537468.654,"total_display":"537,468.65","total_whole":"537,469","shares_owned_after":173833.0,"shares_owned_after_display":"173,833","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-15","filed_date":"2024-10-16","scope":"insider","n_lines":2},{"id":2102157,"accession":"0001415889-24-023657","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001415889-24-023657","line_url":"/filing/0001415889-24-023657","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":62.031553,"price_display":"62.03","price_state":"stated","total_value":620315.53,"total_display":"620,315.53","total_whole":"620,316","shares_owned_after":175793.0,"shares_owned_after_display":"175,793","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-18","filed_date":"2024-09-18","scope":"insider","n_lines":2},{"id":2102147,"accession":"0001415889-24-023657","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-023657","line_url":"/filing/0001415889-24-023657#line-2","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":62.878,"price_display":"62.88","price_state":"stated","total_value":628780.0,"total_display":"628,780.00","total_whole":"628,780","shares_owned_after":173756.0,"shares_owned_after_display":"173,756","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-17","filed_date":"2024-09-18","scope":"insider"},{"id":2930020,"accession":"0001415889-24-021850","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001415889-24-021850","line_url":"/filing/0001415889-24-021850","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":61.74699,"price_display":"61.75","price_state":"stated","total_value":617469.9,"total_display":"617,469.90","total_whole":"617,470","shares_owned_after":168276.0,"shares_owned_after_display":"168,276","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-21","filed_date":"2024-08-21","scope":"insider","n_lines":2},{"id":2930002,"accession":"0001415889-24-021850","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-021850","line_url":"/filing/0001415889-24-021850#line-2","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":61.055,"price_display":"61.06","price_state":"stated","total_value":610550.0,"total_display":"610,550.00","total_whole":"610,550","shares_owned_after":168176.0,"shares_owned_after_display":"168,176","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-20","filed_date":"2024-08-21","scope":"insider"},{"id":2530483,"accession":"0001415889-24-020055","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001415889-24-020055","line_url":"/filing/0001415889-24-020055#line-6","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":55.115,"price_display":"55.12","price_state":"stated","total_value":551150.0,"total_display":"551,150.00","total_whole":"551,150","shares_owned_after":168176.0,"shares_owned_after_display":"168,176","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-24","filed_date":"2024-07-24","scope":"insider"},{"id":2530478,"accession":"0001415889-24-020055","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-24-020055","line_url":"/filing/0001415889-24-020055","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":54.8873382,"price_display":"54.89","price_state":"stated","total_value":548873.382,"total_display":"548,873.38","total_whole":"548,873","shares_owned_after":168176.0,"shares_owned_after_display":"168,176","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-07-23","filed_date":"2024-07-24","scope":"insider","n_lines":2},{"id":2806708,"accession":"0001415889-24-017625","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-017625","line_url":"/filing/0001415889-24-017625#line-2","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":49.426,"price_display":"49.43","price_state":"stated","total_value":494260.0,"total_display":"494,260.00","total_whole":"494,260","shares_owned_after":168176.0,"shares_owned_after_display":"168,176","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-06-18","filed_date":"2024-06-20","scope":"insider"},{"id":3262604,"accession":"0001415889-24-014123","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-24-014123","line_url":"/filing/0001415889-24-014123#line-4","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":45.384,"price_display":"45.38","price_state":"stated","total_value":453840.0,"total_display":"453,840.00","total_whole":"453,840","shares_owned_after":168176.0,"shares_owned_after_display":"168,176","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-22","filed_date":"2024-05-22","scope":"insider"},{"id":3262598,"accession":"0001415889-24-014123","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-014123","line_url":"/filing/0001415889-24-014123#line-2","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":45.164,"price_display":"45.16","price_state":"stated","total_value":451640.0,"total_display":"451,640.00","total_whole":"451,640","shares_owned_after":168176.0,"shares_owned_after_display":"168,176","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-05-21","filed_date":"2024-05-22","scope":"insider"},{"id":2256053,"accession":"0001415889-24-011058","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-24-011058","line_url":"/filing/0001415889-24-011058#line-4","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":38.489,"price_display":"38.49","price_state":"stated","total_value":384890.0,"total_display":"384,890.00","total_whole":"384,890","shares_owned_after":168176.0,"shares_owned_after_display":"168,176","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-04-17","filed_date":"2024-04-17","scope":"insider"},{"id":2256046,"accession":"0001415889-24-011058","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-011058","line_url":"/filing/0001415889-24-011058#line-2","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":38.35,"price_display":"38.35","price_state":"stated","total_value":383500.0,"total_display":"383,500.00","total_whole":"383,500","shares_owned_after":168176.0,"shares_owned_after_display":"168,176","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-04-16","filed_date":"2024-04-17","scope":"insider"},{"id":2743857,"accession":"0001415889-24-007825","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001415889-24-007825","line_url":"/filing/0001415889-24-007825#line-5","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":42.273,"price_display":"42.27","price_state":"stated","total_value":422730.0,"total_display":"422,730.00","total_whole":"422,730","shares_owned_after":156558.0,"shares_owned_after_display":"156,558","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-13","filed_date":"2024-03-13","scope":"insider"},{"id":2743844,"accession":"0001415889-24-007825","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-007825","line_url":"/filing/0001415889-24-007825#line-2","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":41.637,"price_display":"41.64","price_state":"stated","total_value":416370.0,"total_display":"416,370.00","total_whole":"416,370","shares_owned_after":156558.0,"shares_owned_after_display":"156,558","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-03-12","filed_date":"2024-03-13","scope":"insider"},{"id":2130491,"accession":"0001415889-24-005756","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-24-005756","line_url":"/filing/0001415889-24-005756","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":39.5462993,"price_display":"39.55","price_state":"stated","total_value":395462.993,"total_display":"395,462.99","total_whole":"395,463","shares_owned_after":156558.0,"shares_owned_after_display":"156,558","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-28","filed_date":"2024-02-28","scope":"insider","n_lines":2},{"id":2130467,"accession":"0001415889-24-005756","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-24-005756","line_url":"/filing/0001415889-24-005756#line-1","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":39.946,"price_display":"39.95","price_state":"stated","total_value":399460.0,"total_display":"399,460.00","total_whole":"399,460","shares_owned_after":159087.0,"shares_owned_after_display":"159,087","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-02-27","filed_date":"2024-02-28","scope":"insider"},{"id":2221311,"accession":"0001415889-24-001520","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-24-001520","line_url":"/filing/0001415889-24-001520#line-4","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":36.0,"price_display":"36.00","price_state":"stated","total_value":360000.0,"total_display":"360,000.00","total_whole":"360,000","shares_owned_after":151911.0,"shares_owned_after_display":"151,911","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-17","filed_date":"2024-01-18","scope":"insider"},{"id":2221304,"accession":"0001415889-24-001520","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-24-001520","line_url":"/filing/0001415889-24-001520#line-2","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":36.0,"price_display":"36.00","price_state":"stated","total_value":360000.0,"total_display":"360,000.00","total_whole":"360,000","shares_owned_after":151911.0,"shares_owned_after_display":"151,911","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-01-16","filed_date":"2024-01-18","scope":"insider"},{"id":7901880,"accession":"0001415889-23-016423","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001415889-23-016423","line_url":"/filing/0001415889-23-016423#line-6","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":40.394,"price_display":"40.39","price_state":"stated","total_value":403940.0,"total_display":"403,940.00","total_whole":"403,940","shares_owned_after":151911.0,"shares_owned_after_display":"151,911","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-13","filed_date":"2023-12-13","scope":"insider"},{"id":7901873,"accession":"0001415889-23-016423","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-23-016423","line_url":"/filing/0001415889-23-016423","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":39.632227,"price_display":"39.63","price_state":"stated","total_value":396322.27,"total_display":"396,322.27","total_whole":"396,322","shares_owned_after":152554.0,"shares_owned_after_display":"152,554","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-12-12","filed_date":"2023-12-13","scope":"insider","n_lines":2},{"id":8417279,"accession":"0001415889-23-015195","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001415889-23-015195","line_url":"/filing/0001415889-23-015195#line-6","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":39.788,"price_display":"39.79","price_state":"stated","total_value":397880.0,"total_display":"397,880.00","total_whole":"397,880","shares_owned_after":151911.0,"shares_owned_after_display":"151,911","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-15","filed_date":"2023-11-16","scope":"insider"},{"id":8417272,"accession":"0001415889-23-015195","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-23-015195","line_url":"/filing/0001415889-23-015195","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":39.079,"price_display":"39.08","price_state":"stated","total_value":390790.0,"total_display":"390,790.00","total_whole":"390,790","shares_owned_after":151911.0,"shares_owned_after_display":"151,911","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-11-14","filed_date":"2023-11-16","scope":"insider","n_lines":2},{"id":8589808,"accession":"0001415889-23-014366","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-23-014366","line_url":"/filing/0001415889-23-014366#line-2","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":36.52,"price_display":"36.52","price_state":"stated","total_value":365200.0,"total_display":"365,200.00","total_whole":"365,200","shares_owned_after":151911.0,"shares_owned_after_display":"151,911","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-10-17","filed_date":"2023-10-17","scope":"insider"},{"id":8613302,"accession":"0001415889-23-013397","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-23-013397","line_url":"/filing/0001415889-23-013397#line-2","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":39.098,"price_display":"39.10","price_state":"stated","total_value":390980.0,"total_display":"390,980.00","total_whole":"390,980","shares_owned_after":151911.0,"shares_owned_after_display":"151,911","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-09-19","filed_date":"2023-09-19","scope":"insider"},{"id":8479880,"accession":"0001415889-23-012570","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-23-012570","line_url":"/filing/0001415889-23-012570","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":42.407,"price_display":"42.41","price_state":"stated","total_value":424070.0,"total_display":"424,070.00","total_whole":"424,070","shares_owned_after":151911.0,"shares_owned_after_display":"151,911","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-08-22","filed_date":"2023-08-23","scope":"insider","n_lines":2},{"id":8059489,"accession":"0001415889-23-011318","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001415889-23-011318","line_url":"/filing/0001415889-23-011318#line-4","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":40.43,"price_display":"40.43","price_state":"stated","total_value":404300.0,"total_display":"404,300.00","total_whole":"404,300","shares_owned_after":141911.0,"shares_owned_after_display":"141,911","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-07-18","filed_date":"2023-07-19","scope":"insider"},{"id":7842719,"accession":"0001415889-23-010180","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-23-010180","line_url":"/filing/0001415889-23-010180#line-2","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":36.0,"price_display":"36.00","price_state":"stated","total_value":360000.0,"total_display":"360,000.00","total_whole":"360,000","shares_owned_after":141911.0,"shares_owned_after_display":"141,911","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-06-21","filed_date":"2023-06-22","scope":"insider"},{"id":8231589,"accession":"0001415889-23-006740","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-23-006740","line_url":"/filing/0001415889-23-006740#line-2","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":36.0,"price_display":"36.00","price_state":"stated","total_value":360000.0,"total_display":"360,000.00","total_whole":"360,000","shares_owned_after":141911.0,"shares_owned_after_display":"141,911","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-04-18","filed_date":"2023-04-19","scope":"insider"},{"id":9287208,"accession":"0001415889-23-006738","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001415889-23-006738","line_url":"/filing/0001415889-23-006738#line-1","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2984.0,"shares_display":"2,984","price_per_share":49.549,"price_display":"49.55","price_state":"stated","total_value":147854.216,"total_display":"147,854.22","total_whole":"147,854","shares_owned_after":141911.0,"shares_owned_after_display":"141,911","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-27","filed_date":"2023-04-19","scope":"insider"},{"id":8710162,"accession":"0001415889-23-003487","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-23-003487","line_url":"/filing/0001415889-23-003487","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":49.5482984,"price_display":"49.55","price_state":"stated","total_value":495482.984,"total_display":"495,482.98","total_whole":"495,483","shares_owned_after":141911.0,"shares_owned_after_display":"141,911","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-27","filed_date":"2023-02-28","scope":"insider","n_lines":2},{"id":8005744,"accession":"0001415889-23-002956","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-23-002956","line_url":"/filing/0001415889-23-002956#line-2","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2878.0,"shares_display":"2,878","price_per_share":49.26,"price_display":"49.26","price_state":"stated","total_value":141770.28,"total_display":"141,770.28","total_whole":"141,770","shares_owned_after":148927.0,"shares_owned_after_display":"148,927","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-16","filed_date":"2023-02-21","scope":"insider"},{"id":8304233,"accession":"0001415889-23-002714","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001415889-23-002714","line_url":"/filing/0001415889-23-002714#line-3","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":48.394,"price_display":"48.39","price_state":"stated","total_value":483940.0,"total_display":"483,940.00","total_whole":"483,940","shares_owned_after":143477.0,"shares_owned_after_display":"143,477","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-02-15","filed_date":"2023-02-17","scope":"insider"},{"id":8637046,"accession":"0001415889-23-001128","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001415889-23-001128","line_url":"/filing/0001415889-23-001128","is_derivative":false,"issuer_cik":"0001159036","issuer_name":"HALOZYME THERAPEUTICS, INC.","issuer_ticker":"HALO","issuer_name_source":null,"issuer_url":"/issuer/0001159036","owner_cik":"0001507174","owner_name":"LaBarre Michael J.","owner_display_name":"LaBarre Michael J.","owner_url":"/insider/0001507174","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark":"O","role_mark_label":"Officer (SVP, CHIEF TECHNICAL OFFICER)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"SVP, CHIEF TECHNICAL OFFICER","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":50.4590172,"price_display":"50.46","price_state":"stated","total_value":504590.172,"total_display":"504,590.17","total_whole":"504,590","shares_owned_after":144259.0,"shares_owned_after_display":"144,259","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-01-17","filed_date":"2023-01-18","scope":"insider","n_lines":2}],"collapsed":true,"next_cursor":"2023-01-17|8637042","ledger_fault":false,"count":{"value":70,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":70,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":70},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001159036","name":"HALOZYME THERAPEUTICS, INC.","url":"/issuer/0001159036","role":"Officer (SVP, CHIEF TECHNICAL OFFICER)","n_filings":37,"first_seen":"2020-05-21","last_seen":"2025-02-27"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001507174","retrieved_at":"2026-08-24T13:16:29+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}